GlobeImmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences.
Two of the cancer drugs Novartis traded for from GSK--Tafinlar and Mekinist--will post combo survival data at ASCO.
Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash.
Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.
One of the leaders of the CAR-T revolution has now aligned itself in an R&D collaboration with one of the top biotechs to emerge in the hot gene editing field. Juno Therapeutics is tying the knot with Editas on three programs, handing over $47 million in an upfront payment and three years of research support along with up to $690 million in milestones.
After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene therapy designed to durably stymie the lethal HIV with one treatment.
It's time for another FierceBiotech survey! And this time, we've partnered with Bloomberg Intelligence to expand our reach into the global ranks of biopharma execs and analysts.
Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug.
With the aggressive pharmaceutical benefits manager Express Scripts lying in wait for two new cholesterol blockbuster contenders expected to debut this summer, the highly anticipated price war appears to already be well underway.
Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.
Amicus Therapeutics has landed on the European regulatory fast track, potentially shortening the review time for its orphan drug as it prepares filings at home and abroad.
Boston-based PureTech, an investment group which is better known for its high-profile board than its portfolio of upstart life sciences companies, has landed in the U.K. with a plan to raise $160 million on the London stock market.
A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a shoo-in at the FDA. But late Friday evening, Amgen abruptly said it was pulling out of the long-running collaboration on the high-profile IL-17 program after evaluating the likely commercial impact it would face in light of the suicidal thoughts some patients reported during the studies.
Shanghai drug developer Cellular Biomedicine reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday.
A group of Chinese biotech heavyweights are banding together to buy Ambrx, R&D partner to the likes of Bristol-Myers Squibb and Merck, in hopes of making the company a go-to collaborator in their native country.
Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.
Amgen is likely to come in second in the race to launch new cholesterol treatments in the U.S., but the Big Biotech is leading the charge in Europe, securing a crucial regulatory recommendation that clears the way for approval.
Otonomy's treatment for a balance-destroying ear disease missed the mark in a Phase IIb study--but it was close, and the biotech believes the drug did well enough to merit moving forward into late-stage testing.
In this week's EuroBiotech Report, Abivax became the latest French biotech to file for an IPO in its home country, seeking cash ahead of moving an HIV drug into two Phase IIb trials, as well as to support the clinical development of its lead candidate, a therapeutic vaccine against hepatitis B. And more.